According to the reports,Indian pharmaceutical and healthcare industry saw a hectic value due to the merging and acquisition (M&A) activity. The deal valued up to $3.31 million dollar in 2021.

According to VCC Edge during January to June the value touched to $4.32 billion, compared to $2.02 last year at the same period this time.

According to the reports the M&A value came up to $ 1.33 billion last year.

Last year in the second of the M&A deal rose to 53 from 47, as per the reports.

The M&A value rose high due to the Biocon biologics agreement to buy Viatris Inc.’s global biosimilar portfolio for $3.34 billion in February. The deal received the nod from the Competition Commission of India (CCI) last month. Biocon Biologics, a unit of Biocon Ltd, is backed by Abu Dhabi’s state entity ADQ and private equity firms such as True North and Tata Capital.

Ramesh Kannan, partner at healthcare-focused private equity firm Somerset Indus Capital Partners, says, “There is a very clear direction towards aggregation, consolidation and bigger deal sizes in the healthcare and pharmaceuticals space in India.”

Private equity deal during the period rose due to the two big ticket transaction in the healthtech is first was the brain cpaitals agreement to invest in the Citius Tech for $960 million. The other major deal is with the Biofourmis snagged $300 million as part of its Series D funding round led by private equity firm General Atlantic.

“The deal momentum will continue as more foreign companies which are interested in strategic transactions are coming,” adds Kannan.